Recent Advances in Phenylboronic Acid-Based Gels with Potential for Self-Regulated Drug Delivery

Glucose-sensitive drug platforms are highly attractive in the field of self-regulated drug delivery. Drug carriers based on boronic acid (BA), especially phenylboronic acid (PBA), have been designed for glucose-sensitive self-regulated insulin delivery. The PBA-functionalized gels have attracted mor...

Full description

Saved in:
Bibliographic Details
Published in:Molecules (Basel, Switzerland) Switzerland), 2019-03, Vol.24 (6), p.1089
Main Authors: Wang, Chenyu, Lin, Bozhong, Zhu, Haopeng, Bi, Fei, Xiao, Shanshan, Wang, Liyan, Gai, Guangqing, Zhao, Li
Format: Article
Language:English
Subjects:
Aqueous solutions
Cancer therapies
Crosslinking
Diabetes
Diabetes mellitus
diabetes therapy
Drug carriers
Drug delivery
Drug delivery systems
gel
Gels
Glucose
glucose sensitivity
Hydrogels
Insulin
Microgels
Nanoparticles
Phase transitions
phenylboronic acid
Physicochemical properties
Physiology
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Glucose-sensitive drug platforms are highly attractive in the field of self-regulated drug delivery. Drug carriers based on boronic acid (BA), especially phenylboronic acid (PBA), have been designed for glucose-sensitive self-regulated insulin delivery. The PBA-functionalized gels have attracted more interest in recent years. The cross-linked three-dimensional (3D) structure endows the glucose-sensitive gels with great physicochemical properties. The PBA-based platforms with cross-linked structures have found promising applications in self-regulated drug delivery systems. This article summarizes some recent attempts at the developments of PBA-mediated glucose-sensitive gels for self-regulated drug delivery. The PBA-based glucose-sensitive gels, including hydrogels, microgels, and nanogels, are expected to significantly promote the development of smart self-regulated drug delivery systems for diabetes therapy.
ISSN:1420-3049
1420-3049
DOI:10.3390/molecules24061089